Taken together, our results suggest the underlying mechanism of targeting CXCR4 with AMD3100 to inhibit trastuzumab-resistant tumor cell growth operates via mitotic catastrophe and mitotic death. This evidence concerns the gene CXCR4 and neoplasm.